Povetacicept

iStock, Anton Vierietin Gilead, AstraZeneca and Vertex have acquired more than just a therapeutic asset in recent deals. BioSpace takes a look at five recent transactions where the staff was the real centerpiece. Pharma M&A deals tend to revolve around key assets that can bolster the pipeline and provide growth. But sometimes, the buyer sees a lot more in the expertise within the target organization. That was the case with Gilead Sciences’ recent acquisition of Tubulis GmbH, where the antibody-drug conjugate (ADC) biotech will be housed as a specialized R&D unit within the parent company and continue to crank out new assets. With any acquisition, there’s bound to be some redundancies. Often top-level leaders like the CEO move on to lead other companies. But bench-level expertise sometimes can’t be replaced, particularly at platform companies or biotechs developing cutting-edge therapeutics like radiopharmaceuticals. On the flip side is when a company only wants an asset and none of the staff. That was the case when GSK bought the Canadian chronic cough biotech BELLUS Health for $2 billion in 2023. A year later, almost the entire staff was let go as the P2X3 receptor antagonist camlipixant was integrated into the U.K. pharma’s pipeline. Below, BioSpace takes a look at recent deals where the staff was just as much of a prize as the assets within the biotech. Gilead snags an ADC R&D factory thanks to Tubulis There is nothing hotter in the cancer space than ADCs right now. To get up to speed, Gilead bought Tubulis for $5 billion earlier this month, pledging to tuck the biotech in as a dedicated ADC R&D unit. Tubulis CEO Dominik Schumacher, who is also co-founder of the German company, said the two companies will work together now to incorporate the biotech’s platform and capabilities into Gilead’s oncology research group. “We and Gilead believe our team is one of our greatest assets and was an important consideration as part of this transaction,” Schumacher told BioSpace in an email . “We strongly believe that Gilead saw not only the full potential and depth of our pipeline and technologies but also the expertise of our world-class team as a core asset.” Gilead and Tubulis have worked together since 2024 through a licensing deal. The initial focus post-merger will be on the ovarian cancer asset TUB-040. But Gilead executives were clear that the acquisition offers much more. “Oncology, ovarian cancer and then other areas in oncology are the first directions, but there is real opportunity to build out and move into inflammation and into virology,” Chief Medical Officer Dietmar Berger said on a conference call discussing Gilead’s recent deal strategy. CEO Daniel O’Day agreed that bringing the partners together under one wing was the best way to maximize value and blend the scientific expertise on both sides. “There is no one size fits all for how those partnerships will eventually evolve,” O’Day said. “Some of them we feel just would be helpful for us to fully integrate into the further strength of Gilead.” Mergers & acquisitions Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis The acquisition of Tubulis GmbH—Gilead Sciences’ latest of the year after buying Arcellx and Ouro Medicines—brings into the fold a novel ovarian cancer candidate that has demonstrated promising mid-stage data. April 7, 2026 · 2 min read · Heather McKenzie Read more Biogen gets launch ready with Apellis In the $5.6 billion acquisition of Apellis Pharmaceuticals, Biogen wasn’t after the scientists exactly. Those experts had already done their work, bringing kidney disease drug Empaveli and eye disease therapy Syfovre to FDA approval in 2021 and 2023, respectively. Instead, Biogen wanted Apellis’ nephrology team to help launch an asset from a previous deal called felzartamab, a CD38 targeting antibody being tested in three different kidney diseases. “We just think that if the clinical trials work out for felzartamab as we hope, that we will have a running start into the launch, and we could actually potentially achieve peak sales faster than we would if we were just doing this on our own,” CEO Chris Viehbacher said on a conference call discussing the deal . The strategy makes sense. Kidney disease is a new area for Biogen, but not for heavy-hitters like Novartis, which is developing medicines in the space as well. With Apellis’ experience with Empaveli —approved for p aroxysmal octurnal hemoglobinuria , C3 glomerulopathy and g lomerulonephritis —Biogen will have the expertise to pull off the launch. “We feel comfortable that we’re going to be able to work with the Apellis teams to really pull the teams together and do even more with these two products than either company could do on their end,” Viehbacher said. Mergers & acquisitions Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy In addition to delivering two approved medicines to Biogen’s portfolio, the acquisition of Apellis Pharmaceuticals will support the future launch of the pharma’s own kidney disease asset, currently in multiple Phase 3 trials. March 31, 2026 · 4 min read · Annalee Armstrong Read more AstraZeneca buys a radiopharma brain trust in Fusion If you want to develop therapies using radioactive materials, you better find yourself some pros. That’s exactly what AstraZeneca did in 2024, amid a pharma deal craze for radiopharmaceuticals. The U.K. pharma bought Fusion Pharmaceuticals for $2.4 billion in March 2024, adding on a portfolio of radioconjugate assets including a lead prostate cancer med called FPI-2265. But equally valuable to AstraZeneca were the experts who developed Fusion’s pipeline—and helping to establish a base in Canada. “The acquisition brings new expertise and pioneering R&D, manufacturing and supply chain capabilities in actinium-based RCs to AstraZeneca,” the pharma said in a statement at the time of the acquisition. “It also strengthens the company’s presence in and commitment to Canada.” That supply chain aspect is key in radiopharma, where manufacturing has been a top concern for budding biotechs and pharmas in the space. Fusion in particular had an established supply chain of actinium-225, which supported its next-gen radioconjugate platform. The companies had already worked together, getting to know each other in a licensing collaboration before AstraZeneca ultimately swallowed the biotech whole. “This acquisition combines Fusion’s expertise and capabilities in radioconjugates, including our industry-leading radiopharmaceutical R&D, pipeline, manufacturing and actinium-225 supply chain, with AstraZeneca’s leadership in small molecules and biologics engineering to develop novel radioconjugates,” Fusion CEO John Valliant said in a statement at the time. Deals AstraZeneca Buys Fusion in Potential $2B Deal, Joins Radiopharma Buying Spree Following in the footsteps of Bristol Myers Squibb and Eli Lilly, AstraZeneca on Tuesday jumped into the radiopharmaceuticals space by acquiring Fusion Pharmaceuticals in a deal worth $2.4 billion. March 19, 2024 · 3 min read · Tristan Manalac Read more AstraZeneca tucks Amolyt into Alexion to continue rare disease mission In rare disease, it’s best to go with the pros. That was AstraZeneca’s thinking in March 2024, when Amolyt Pharma was tucked into its existing Alexion rare disease unit for about $1.06 billion. You may remember Alexion as one of the biggest deals of 2020 at $39 billion, and one where the workforce and footprint were just as important as the assets. The unit has retained the Alexion name since joining the U.K. pharma and Amolyt was purchased to fit neatly inside. “Alexion is looking forward to welcoming talent from Amolyt Pharma,” AstraZeneca said in a statement at the time of the deal. Amolyt in particular would boost Alexion’s pipeline beyond complement inhibition and expand on existing work in bone metabolism. Amolyt’s lead asset was eneboparatide, under development for hypoparathyroidism. “As leaders in rare disease, Alexion is uniquely positioned to drive the late-stage development and global commercialization of eneboparatide,” Alexion CEO Marc Dunoyer said at the time. “We believe this program, together with Amolyt’s talented team, expertise and earlier pipeline, will enable our expansion into rare endocrinology.” Amolyt CEO Thierry Abribat recently received an award for best biotech exit. The executive credited the Amolyt team, which is still working to get eneboparatide approved. “This award is first and foremost for the Amolyt Pharma team. A successful exit is fantastic, but it’s not the end of the story. The story will end when our drug candidates are available to patients internationally,” Abribat said in his acceptance speech, translated from French by Google Translate. “The Amolyt Pharma team, now part of Alexion Pharmaceuticals, Inc., is working tirelessly every day to complete the development of eneboparatide for the treatment of hypoparathyroidism and to continue developing the other products in our portfolio.” Deals AstraZeneca Boosts Rare Disease Portfolio with $1.05B Amolyt Acquisition At the center of the deal is Amolyt Pharma’s late-stage candidate eneboparatide for the rare disease hypoparathyroidism. AstraZeneca also gains ownership of AZP-3813, which is being assessed for acromegaly in a Phase I trial. March 14, 2024 · 2 min read · Tristan Manalac Read more Vertex anchors pipeline-in-a-product with Alpine team One of the Holy Grails of pharma is always the pipeline-in-a-product asset—a drug that can be used in multiple indications and secure numerous approvals. That’s what Vertex Pharma was seeking with the $4.9 billion acquisition of Alpine Immune Sciences in April 2024. At the center of the deal was povetacicept, a dual antagonist of the BAFF and APRIL cytokines believed to activate B cells, under development initially for IgA nephropathy (IgAN). The deal was a good fit for Vertex, which was looking to pick up assets in specialty markets, CEO Reshma Kewalramani said at the time. But she also credited the Alpine team—specifically welcoming them to Vertex—as well as the potential of the biotech’s protein engineering and immunotherapy capabilities. Alpine CEO Mitchell Gold said the fit was clear on a person-to-person level, too. “It became clear during our discussions with the Vertex team that we share many core values, including a commitment to patients, our employees, and an intense drive for innovation,” Gold said in a statement at the time of the deal . “We could not have picked a better steward of povetacicept,” he added after Vertex posted late-stage results for the asset in March. Honorable mention: Galapagos seeks new employees through acquisitions This deal has not exactly happened—yet. But Galapagos CEO Henry Gosebruch told BioSpace in January that part of his goal in finding companies to acquire is to retain the workforce . He framed this as a plus in negotiating deals because the target company leadership won’t have to worry about losing staff. “One of the things we can offer to a potential transaction party is that if there’s a strong R&D team or a strong commercial team, they could, as a full team, come to Galapagos and be our team going forward,” Gosebruch said. .responsive-container { display: flex; flex-wrap: wrap; border: 1px solid #ededed; font-family: Helvetica, Arial, Sans-Serif; padding: 20px 20px 10px 20px; } .column-left { flex: 1; max-width: 45%; padding: 20px 20px 10px 20px; } .column-right { flex: 2; padding: 20px 20px 10px 20px; } @media (max-width: 768px) { .column-left, .column-right { max-width: 100%; flex: 100%; padding: 10px 0; } } Subscribe to BioPharm Executive! Market insights, trending business and policy stories for biopharma leaders hbspt.forms.create({ region: "na1", portalId: "4413123", formId: "7c139b3c-ff0b-44e0-bffe-f449801dca59", onFormSubmitted: function($form, data) { window.dataLayer = window.dataLayer || []; window.dataLayer.push({ 'event': 'GTMevent', 'event_name': 'newsletter_sign_up' }); } });

点击“蓝字”关注我们 2025年，改善全球肾脏病预后组织（KDIGO）再次更新IgA肾病管理指南，此后，美国食品药品监督管理局（FDA）又加速批准了3种IgA肾病治疗药物，其中2种药物的作用机制与既往获批药物存在本质差异。为此，KDIGO IgA肾病工作组特撰写本评论，明确新型药物在IgA肾病整体治疗策略中的定位，为临床实践提供过渡性指导，同时为后续指南的全面更新奠定基础。本文将围绕该评论核心内容，系统解读补体抑制剂与B细胞调节剂等新型药物的临床价值、作用机制及治疗定位，助力临床医师精准应用新型疗法，改善IgA肾病患者预后。 一 IgA肾病治疗领域的快速发展与指南更新背景 KDIGO于2021年更新的《肾小球疾病临床实践指南》，是自首版肾小球疾病指南发布十余年后的首次重大更新，其发布背景是长期以来肾小球疾病药物研发进展缓慢，临床治疗手段相对匮乏。但自2021年起，这一局面得到显著改善，多种肾小球疾病的新型治疗药物经临床试验验证有效并获得监管机构批准，其中IgA肾病的治疗进展最为突出，成为该领域的研究热点。 为紧跟新型治疗药物的发展步伐，KDIGO于2025年再次更新了IgA肾病临床实践指南，进一步优化了治疗策略。值得关注的是，在该版指南发布后，FDA又加速批准了3种额外的IgA肾病治疗药物。由于其中2种药物的推定作用机制与既往获批药物存在明显差异，KDIGO IgA肾病工作组认为，在获得这些药物及其他潜在疗法的更多证据之前，无需进行指南的全面更新，而是通过撰写简短评论，明确新型药物在IgA肾病整体治疗策略中的定位，为临床实践提供及时、有效的指导。 除本文重点讨论的已获批药物外，目前还有多种药物处于Ⅲ期临床试验阶段，涵盖多个治疗靶点，包括B细胞调节剂（povetacicept[泊维他西普]、泰它西普、zigakibart[泽戈奇拜单抗]）、浆细胞清除剂（felzartamab[菲泽妥单抗]、mezagitamab[迈泽妥单抗]）、补体抑制剂（瑞利珠单抗、sefaxersen）、内皮素受体拮抗剂（zibotentan[齐泊腾坦]）、非甾体类盐皮质激素受体拮抗剂（非奈利酮）及醛固酮合酶抑制剂（vicadrostat），未来有望进一步丰富IgA肾病的治疗选择。 二 IgA肾病新型获批药物的临床研究与治疗定位 2.1 内皮素A型受体拮抗剂：阿曲生坦 2025年IgA肾病指南更新后不久，阿曲生坦获得FDA加速批准，用于治疗存在快速疾病进展风险的成人原发性IgA肾病患者，这类患者通常被定义为尿蛋白/肌酐比值（uPCR）≥1.5 g/g。该批准基于Ⅲ期ALIGN试验（阿曲生坦治疗IgA肾病患者，NCT04573478）的研究结果。 与司帕生坦类似，阿曲生坦属于内皮素A型受体拮抗剂，但与司帕生坦不同的是，阿曲生坦不阻断血管紧张素受体，因此在ALIGN试验中，其给药方式为在肾素-血管紧张素系统抑制剂（RASi）治疗的基础上联合使用。治疗36周后，接受阿曲生坦治疗的受试者uPCR较基线下降38.1%，而安慰剂组仅下降3.1%，两组治疗差异达36.1%（P<0.001），显著优于安慰剂。安全性方面，除阿曲生坦组患者出现轻度液体潴留外，两组不良事件发生率无显著差异。 目前ALIGN试验仍在持续进行中，旨在进一步明确与单独使用RASi相比，阿曲生坦是否能延缓IgA肾病患者估算肾小球滤过率（eGFR）的下降。在IgA肾病治疗框架（图1）中，阿曲生坦将作为司帕生坦的替代选择，为临床提供更多治疗方案。 图1. IgA肾病（IgAN）中的治疗靶点及治疗定位 2.2 补体抑制剂：伊普可泮 大量证据表明，补体系统（尤其是旁路途径）在IgA肾病的肾小球炎症损伤中发挥重要作用，同时补体还可能通过肾小管间质区的促纤维化作用，参与肾功能的慢性进行性损伤。为验证补体抑制剂在IgA肾病中的治疗效果，研究人员开展了Ⅲ期APPLAUSE-IgAN试验（LNP023治疗原发性IgA肾病患者的疗效与安全性研究，NCT04578834），采用口服补体B因子抑制剂伊普可泮，其作用机制为阻断补体旁路途径。 治疗36周后，接受伊普可泮治疗的受试者uPCR较安慰剂组降低38.3%（P<0.001），基于该研究结果，FDA加速批准伊普可泮用于存在快速疾病进展风险的成人原发性IgA肾病患者。2025年10月16日，APPLAUSE-IgAN试验正式完成，新闻稿指出伊普可泮在eGFR保护方面具有显著疗效，但未公布具体数据。伊普可泮的全面监管批准仍需等待其与单独使用RASi相比，对eGFR下降影响的进一步分析结果。 补体抑制治疗的主要顾虑之一是增加包膜细菌感染的风险，因此在使用伊普可泮前，需对患者进行疫苗接种或预防性使用抗生素。在临床试验中，此类感染发生率低于0.5%，且所有感染患者经适当抗生素治疗后均痊愈。总体而言，伊普可泮治疗组与安慰剂组的安全性无明显差异。 2.3 B细胞调节剂：斯贝利单抗 斯贝利单抗是最新加入IgA肾病治疗选择的药物，其为人源化单克隆抗体，靶向作用于B细胞存活因子——增殖诱导配体（APRIL）。基于Ⅲ期VISIONARY试验（斯贝利单抗治疗IgA肾病的Ⅲ期试验，NCT05248646）的研究结果，FDA加速批准斯贝利单抗用于存在疾病进展风险的成人原发性IgA肾病患者（无uPCR标准限制）。 治疗40周后，斯贝利单抗治疗组受试者uPCR较基线下降50.2%，而安慰剂组则升高2.1%，斯贝利单抗组蛋白尿降幅较安慰剂组达51.2%（P<0.001）。作为直接作用于B细胞的治疗药物，抗APRIL疗法有望减少致病性IgA的产生。VISIONARY试验的药效学研究显示，斯贝利单抗治疗组患者的半乳糖缺乏型IgA1（Gd-IgA1）下降近70%，总IgA下降68.8%，IgM下降74.5%，IgG下降35.0%。 安全性方面，斯贝利单抗组与安慰剂组不良事件发生率无显著差异。约8%的斯贝利单抗治疗患者产生具有中和能力的抗药物抗体，此类患者的蛋白尿降幅略低于未产生抗药物抗体的患者（-42% vs. -53%），但这种差异的临床相关性仍需进一步明确。目前VISIONARY试验仍在进行中，以确定斯贝利单抗对eGFR下降的影响。 2.4 B细胞调节剂：阿塞西普 另一项采用B细胞治疗药物的Ⅲ期临床试验（atacicept[阿塞西普]）近期已完成，目前正在接受FDA审查。阿塞西普是跨膜激活剂及钙调亲环素配体相互作用因子（TACI）受体与IgG的融合蛋白，TACI是APRIL和B细胞活化因子（BAFF）的共同B细胞表面受体，因此阿塞西普可同时阻断这两种B细胞存活因子的活性。其中，APRIL在浆细胞和浆母细胞分化中发挥重要作用，而BAFF则介导B细胞的存活与成熟。理论上，同时靶向BAFF和APRIL的治疗效果可能优于单独阻断APRIL。 为验证这一假设，研究人员开展了ORIGIN 3研究（阿塞西普治疗IgA肾病患者，NCT04716231），结果显示，治疗36周后，阿塞西普组uPCR下降45.7%，安慰剂组下降6.8%，阿塞西普组的治疗优势达41.8%（P<0.001）。阿塞西普组患者治疗36周后Gd-IgA1下降68%，总IgA下降63.5%，IgM下降74.6%，IgG下降35.5%，与药效学机制一致。安全性方面，阿塞西普组与安慰剂组不良事件发生率无显著差异。 目前ORIGIN试验仍在进行中，以明确阿塞西普对eGFR下降的影响。但就目前数据而言，尚难以区分选择性APRIL拮抗剂与双重BAFF/APRIL拮抗剂在IgA肾病治疗中的疗效与安全性差异。 三 IgA肾病治疗策略的优化与临床实践建议 3.1 治疗药物的选择与定位原则 目前IgA肾病的治疗面临两大挑战：一是一线治疗药物的选择，二是最佳治疗持续时间的确定。所有已获批药物在减少蛋白尿和延缓eGFR下降方面均显著优于单独使用RASi（表1），但由于缺乏头对头比较研究，无法根据蛋白尿降幅或eGFR保护效果对这些药物进行排序，因此表1中的不同试验结果不应直接对比。 表1. 现有及在研IgA肾病治疗药物Ⅲ期临床试验蛋白尿与eGFR数据 注：24小时尿蛋白较基线变化；总斜率；经主要支持性随机系数分析计算。eGFR：估算肾小球滤过率；IgAN：IgA肾病；uPCR：尿蛋白/肌酐比值；NA：本文撰写时尚未公布。 目前，阿曲生坦、伊普可泮和斯贝利单抗对eGFR影响的Ⅲ期数据尚待公布，但斯贝利单抗和阿塞西普的Ⅱ期试验数据显示，这两种药物对GFR具有良好的稳定作用。除疗效因素外，药物的可及性和成本也将影响临床治疗选择。 基于IgA肾病发病机制的“四重打击学说”，临床治疗应根据药物的推定作用机制，匹配其靶向的“打击环节”（图1）。其中，第1~3重打击描述了循环致病性IgA的产生、IgA免疫复合物（IgA-IC）的形成以及这些免疫复合物在肾小球系膜区的沉积；目前致病性IgA常被等同于Gd-IgA1，但这一认知可能过于简化，致病性IgA的具体形式仍需进一步明确。尽管如此，能够减少Gd-IgA1或总IgA产生的药物，有望有效针对第1~3重打击。 第4重打击描述了致病性IgA沉积对肾脏的影响，以及系膜区免疫复合物蓄积所激活的多种损伤途径；能够减轻肾小球炎症或阻断补体的药物，有望有效针对第4重打击。 图1（改编自2025年KDIGO IgA肾病指南更新中的图3）展示了不同药物类别与其预期靶向的致病环节的匹配关系，需注意的是：该匹配关系聚焦于药物的主要作用，所有药物均可能具有潜在的有益次要作用（如内皮素受体拮抗剂[ERA]/双重内皮素血管紧张素受体拮抗剂[DEARA]可能具有抗炎作用）；部分患者可能从新型治疗药物的联合使用中获益，但目前尚无相关联合用药数据，因此图1未强调联合治疗策略；药物的排列顺序不代表其疗效或安全性的推荐等级或使用顺序。 3.2 长期治疗的安全性考量与特殊人群管理 大多数IgA肾病治疗药物可能需要长期使用（持续使用或周期性使用）。目前已知，在免疫介导性疾病中，长期BAFF抑制具有良好的耐受性，但关于APRIL抑制或BAFF/APRIL双重抑制的长期安全性数据仍缺乏。长期补体抑制的安全性也需进一步关注，尽管慢性补体抑制（尤其是C5拮抗）在非典型溶血性尿毒症综合征、阵发性睡眠性血红蛋白尿症和C3肾小球病中已显示出良好的安全性。 图1还提示，对于第1~3重打击与慢性肾脏病（CKD）应同步干预。IgA肾病患者确诊时，许多已处于中度晚期CKD阶段，因此早期干预CKD具有重要意义，但具体治疗方案需个体化。由于进展性CKD的部分损伤机制与第4重打击启动的损伤机制相似，因此将第4重打击与CKD分开考量可能存在一定局限性，但这种分类方式有助于梳理治疗策略。 值得注意的是，多项IgA肾病Ⅲ期临床试验的显著发现是，在临床试验范围内，所有IgA肾病亚组患者（不同种族、GFR水平、蛋白尿水平、系膜细胞增生[M]、内皮细胞增生[E]、节段性硬化[S]、间质纤维化/肾小管萎缩[T]及新月体[C]评分[MEST-C评分]），无论接受内皮素-1拮抗、补体抑制还是B细胞生长因子拮抗治疗，均能获得同等获益。这一发现支持KDIGO的推荐意见：肾活检结果仅用于预后评估，不用于指导治疗决策。 3.3 治疗策略的未来展望 随着IgA肾病新型治疗药物的不断获批，图1中的治疗框架将不断完善和定期更新，纳入新的药物或药物类别。随着更多临床试验数据、真实世界数据和验证生物标志物数据的积累，未来有望明确推荐特定治疗药物或联合治疗方案作为理想的一线治疗选择。此外，随着致病性IgA具体形式的进一步明确（可能涵盖在Gd-IgA1的范畴内），以及能够追踪致病环节和肾脏对损伤及治疗反应的生物标志物的出现，图1的治疗框架将得到进一步细化。 四    总结与展望 近年来，IgA肾病治疗领域迎来快速发展，新型治疗药物的获批显著丰富了临床治疗选择，推动治疗模式从“支持治疗”向“对因治疗”转变。本评论作为2025年KDIGO IgA肾病指南的过渡性指导，明确了补体抑制剂（伊普可泮）、B细胞调节剂（斯贝利单抗、阿塞西普）及内皮素A型受体拮抗剂（阿曲生坦）等新型药物的治疗定位，为临床医师提供了及时的实践指导。 需要强调的是，本评论未涵盖IgA肾病治疗中的诸多重要问题，例如低水平蛋白尿与IgA肾病不良预后的关联、血尿的临床意义、维持治疗、联合治疗、治疗持续时间及治疗转换等。这些问题将在KDIGO IgA肾病指南的下一次正式更新中得到重点探讨。 未来，随着更多临床试验和真实世界研究的开展，IgA肾病的治疗策略将进一步优化，实现更精准的个体化治疗，最终改善患者的长期预后。同时，随着对疾病发病机制的深入探索，有望发现更多新的治疗靶点，推动IgA肾病治疗领域的持续突破。 来源：Kidney Int. 2026 Mar 31:S0085-2538(26)00213-9. doi: 10.1016/j.kint.2026.03.003. 声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。 最新《国际糖尿病》读者专属微信交流群建好了，快快加入吧！扫描左边《国际糖尿病》小助手二维码（微信号：guojitnb），回复“国际糖尿病读者”，ta会尽快拉您入群滴！ （来源：《肾医线》编辑部）